MedTrace Logo

Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects

NCT02621489 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2023-04-20

No results posted yet for this study

Summary

The aim of the study is to use Exenatide long-acting release (LAR) \[Bydureon\] to minimize vascular remodeling and neointima formation after Percutaneous Coronary Intervention (PCI) and to accelerate stent endothelialisation.

Conditions

Interventions

DRUG

Bydureon

2 mg Once Weekly

DRUG

Humulin kwickpen

Humulin kwickpen 10U QD at bedtime

DRUG

Metformin

Metformin 1g BID

Sponsors & Collaborators

Principal Investigators

  • Thomas Nyström · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2022-08-31
Completion
2022-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02621489 on ClinicalTrials.gov